Showing 2781-2790 of 7598 results for "".
- Study Highlights Orofacial Anomalies in Kindler Epidermolysis Bullosahttps://practicaldermatology.com/news/orofacial-anomalies-in-kindler-epidermolysis-bullosa/2462441/A new study in JAMA Dermatology suggests that hypoplastic pitted amelogenesis imperfecta is a feature of Kindler epidermolysis bullosa (KEB). "Kindler epidermolysis bullosa is a genetic skin-blistering disease associated with recessive inherited pathogenic varia
- American Acne and Rosacea Society (AARS) Now Accepting Research Grant Award Applicationshttps://practicaldermatology.com/news/the-american-acne-and-rosacea-society-aars-is-now-accepting-applications-for-research-grant-awards/2462440/The American Acne and Rosacea Society (AARS) has announced the commencement of its grant application cycle for AARS Clinical Research Awards ($10K) and the prestigious AARS Research Scholar Award ($75K). According to a press release, the AARS offers its Clinical Research Awards for the a
- Oxidative Stress Linked with Acne Severity: Analysishttps://practicaldermatology.com/news/circulating-biomarkers-of-oxidative-stress-in-acne-vulgaris/2462438/Biomarkers of oxidative stress correlated with the severity of acne vulgaris, according to a recent review published in the Archives of Dermatological Research. "The relationship between acne vulgaris and oxidative stress biomarkers lacks a clear consensus," the authors wrote. "
- Shaperon Enrolls First Patient in Phase 2 Clinical Trial for Atopic Dermatitis Therapy 'Nugel'https://practicaldermatology.com/news/shaperon-enrolls-first-patient-in-phase-2-clinical-trial-for-atopic-dermatitis-therapy-nugel/2462439/Shaperon announced the enrollment of the first patient in the phase 2 clinical trial for atopic dermatitis treatment candidate Nugel. The trial will evaluate the efficacy of Nugel in improving the Eczema Area Severity Index (EASI) across a cohort of 210 patients with mild to moderate atop
- Mediterranean Diet Adherence Not a Factor in Diagnosis or Severity of Acne: Studyhttps://practicaldermatology.com/news/mediterranian-diet-not-linked-with-acne-development-study/2462437/Results from a new analysis in the Journal of Health, Population, and Nutrition failed to show a link between adherence to a Mediterranean diet and an impact on acne severity or diagnosis. "Western diets, characterized by a high glycemic index and dairy content, can be risk fact
- New Analysis Provides Evidence-based Recommendations for Vitiligo in Pediatric Patientshttps://practicaldermatology.com/news/evidence-based-recommendations-for-treating-vitiligo-in-pediatric-patients-insights-from-comprehensive-review/2462436/A new consensus statement published in JAMA Dermatology provided evidence-based expert recommendations for the treatment of vitiligo in pediatric, adolescent, and young adult patients. The authors undertook a rigorous examination of existing literature and expert consensus, aimi
- Almirall Partners with Eloxx Pharmaceuticals to Target Rare Dermatological Diseaseshttps://practicaldermatology.com/news/almirall-partners-with-eloxx-pharmaceuticals-to-target-rare-dermatological-diseases/2462435/Almirall and Eloxx Pharmaceuticals, Inc., announced today that they have partnered to exclusively license ZKN-013, in what they call a "potential game-changer" for the treatment of rare dermatological disorders. The agreement grants Almirall global rights to develop
- Analysis of Dermatology Mobile Apps with AI Capability Reveals Weaknesses, Transparency Concernshttps://practicaldermatology.com/news/analysis-of-dermatology-mobile-apps-reveals-weaknesses-transparency-concerns/2462434/A new analysis of dermatology mobile applications (apps) revealed transparency, validation, and accuracy concerns. "With advancements in mobile technology and artificial intelligence (AI) methods, there has been a substantial surge in the availability of direct-to-consumer mobile applicat
- New Data on Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in ADhttps://practicaldermatology.com/news/new-data-on-long-term-efficacy-of-nemolizumab-in-prurigo-nodularis-and-its-durability-in-ad-1/2462433/Galderma announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.[1] Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of p
- LEO Pharma Presents New Long-Term Adbry (Tralokinumab-ldrm) Data in Adults with Moderate-to-Severe ADhttps://practicaldermatology.com/news/leo-pharma-presents-new-long-term-adbry-tralokinumab-ldrm-data-in-adults-with-moderate-to-severe-ad/2462432/LEO Pharma unveiled new data analyzing the long-term therapeutic response of treatment with Adbry (tralokinumab-ldrm) in adults with moderate-to-severe atopic dermatitis (AD). The findings were shared via an e-poster at the 82nd American Academy of Dermatology (AAD) Congress in San Diego.[1]